Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Bladder Cancer

Free Subscription 20.03.2023 1 Am J Surg Pathol 1 Ann Surg Oncol 2 Anticancer Drugs 1 Arch Esp Urol 2 Arch Ital Urol Androl 1 Biosens Bioelectron 1 Biotechnol Appl Biochem 1 Cancer Cell Int 1 Cancer Immunol Immunother 1 Cancer Med 1 Cancer Treat Rev 3 Cancers (Basel) 1 Chirurgia (Bucur) 1 Clin Genitourin Cancer 1 Clin Oncol (R Coll Radiol) 1 Comput Methods Programs Biomed 1 Diagnostics (Basel) 1 EBioMedicine 5 Eur Urol 1 Eur Urol Oncol 1 Front Immunol 1 Front Oncol 1 Front Public Health 1 Front Surg 1 Gene 1 Hum Exp Toxicol 4 Int J Mol Sci 1 Int J Urol 2 J Clin Med 1 J Laparoendosc Adv Surg Tech A 2 J Urol 1 Medicine (Baltimore) 1 Molecules 1 Nat Rev Clin Oncol 1 Naunyn Schmiedebergs Arch Pharmacol 1 Neurourol Urodyn 1 Panminerva Med 1 Pathol Res Pract 1 Prog Urol 1 Sci Rep 1 Stem Cell Investig 1 Tissue Cell 4 Transl Androl Urol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Surg Pathol

1. FATIMA A, Russell DH, Epstein JI
   Nested Subtype of Urothelial Carcinoma in the Upper Urinary Tract: A Series of 15 Cases.
   Am J Surg Pathol. 2023;47:461-468.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

2. YANAGISAWA T, Miki J, Matsukawa A, Iwatani K, et al
   ASO Author Reflections: Is T1HG Bladder Cancer a Good Candidate for En Bloc Resection?
   Ann Surg Oncol. 2023 Mar 12. doi: 10.1245/s10434-023-13291.
   PubMed        
   
   

   
   Anticancer Drugs

3. WANG L, Shi G, Zhao G, He W, et al
   Efficacy and safety of enfortumab vedotin in the treatment of advanced urothelial carcinoma: a systematic review and meta-analysis.
   Anticancer Drugs. 2023;34:473-478.
   PubMed         Abstract available
   
   
4. JIN J, Yang Q, Yu Y, Chen L, et al
   Complete response to tislelizumab in a metastatic urothelial carcinoma after surgery associated with high tumor mutational burden: a case report.
   Anticancer Drugs. 2023;34:595-598.
   PubMed         Abstract available
   
   

   
   Arch Esp Urol

5. ZHANG X, Liu H, Zhang J, Wang Z, et al
   Fibronectin-1: A Predictive Immunotherapy Response Biomarker for Muscle‑Invasive Bladder Cancer.
   Arch Esp Urol. 2023;76:70-83.
   PubMed         Abstract available
   
   

   
   Arch Ital Urol Androl

6. JARIMBA R, Quaresma V, Pedroso Lima J, Eliseu M, et al
   Predicting bladder cancer risk in patients with hematuria. A single-centre retrospective study.
   Arch Ital Urol Androl. 2023 Mar 15. doi: 10.4081/aiua.2023.11026.
   PubMed         Abstract available
   
   
7. TZELVES L, Katsimperis S, Bellos T, Berdempes M, et al
   Anthropometric characteristics and relationship with non-muscle invasive bladder cancer in Greece: A case-control study.
   Arch Ital Urol Androl. 2023 Mar 15. doi: 10.4081/aiua.2023.11266.
   PubMed         Abstract available
   
   

   
   Biosens Bioelectron

8. WANG J, Meng X, Yu M, Li X, et al
   A novel microfluidic system for enrichment of functional circulating tumor cells in cancer patient blood samples by combining cell size and invasiveness.
   Biosens Bioelectron. 2023;227:115159.
   PubMed         Abstract available
   
   

   
   Biotechnol Appl Biochem

9. HANNA DH, Aziz MM, Shafee EE
   Effective-by-method for the preparation of folic acid coated TiO(2) nanoparticles with high targeting potential for apoptosis induction against bladder cancer cells (T24).
   Biotechnol Appl Biochem. 2023 Mar 11. doi: 10.1002/bab.2456.
   PubMed         Abstract available
   
   

   
   Cancer Cell Int

10. KE M, Sun N, Lin Z, Zhang P, et al
    SNHG18 inhibits bladder cancer cell proliferation by increasing p21 transcription through destabilizing c-Myc protein.
    Cancer Cell Int. 2023;23:48.
    PubMed         Abstract available
    
    

    
    Cancer Immunol Immunother

11. SEMENIUK-WOJTAS A, Poddebniak-Strama K, Modzelewska M, Baryla M, et al
    Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer.
    Cancer Immunol Immunother. 2023 Mar 16. doi: 10.1007/s00262-023-03376.
    PubMed         Abstract available
    
    

    
    Cancer Med

12. ZHANG W, Zhang Z, Xiao W, Wang Y, et al
    Multiple directional DWI combined with T2WI in predicting muscle layer and Ki-67 correlation in bladder cancer in 3.0-T MRI.
    Cancer Med. 2023 Mar 14. doi: 10.1002/cam4.5782.
    PubMed         Abstract available
    
    

    
    Cancer Treat Rev

13. ASCIONE CM, Napolitano F, Esposito D, Servetto A, et al
    Role of FGFR3 in bladder cancer: Treatment landscape and future challenges.
    Cancer Treat Rev. 2023;115:102530.
    PubMed         Abstract available
    
    

    
    Cancers (Basel)

14. ZHU J, Li Y, Luo Y, Xu J, et al
    Correction: Zhu et al. A Feedback Loop Formed by ATG7/Autophagy, FOXO3a/miR-145 and PD-L1 Regulates Stem-like Properties and Invasion in Human Bladder Cancer. Cancers 2019, 11, 349.
    Cancers (Basel). 2023;15:1403.
    PubMed         Abstract available
    
    
15. HURLE R, Soria F, Contieri R, Avolio PP, et al
    Evaluating the Protective Effect of Intravesical Bacillus Calmette-Guerin against SARS-CoV-2 in Non-Muscle Invasive Bladder Cancer Patients: A Multicenter Observational Trial.
    Cancers (Basel). 2023;15:1618.
    PubMed         Abstract available
    
    
16. CELADA LUIS G, Albers Acosta E, de la Fuente H, Velasco Balanza C, et al
    A Comprehensive Analysis of Immune Response in Patients with Non-Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2023;15:1364.
    PubMed         Abstract available
    
    

    
    Chirurgia (Bucur)

17. CATA ED, Andras I, Popa A, Medan P, et al
    Robotic Radical Cystectomy with Intracorporeal Urinary Diversion - Tips and Tricks.
    Chirurgia (Bucur). 2023;118:63-72.
    PubMed         Abstract available
    
    

    
    Clin Genitourin Cancer

18. VAN GINKEL N, van Gennep EJ, Oosterbaan L, Greidanus J, et al
    Added Clinical Value of (18)F-FDG-PET/CT to Stage Patients With High-Risk Non-Muscle Invasive Bladder Cancer Before Radical Cystectomy.
    Clin Genitourin Cancer. 2023 Feb 22:S1558-7673(23)00037.
    PubMed         Abstract available
    
    

    
    Clin Oncol (R Coll Radiol)

19. PHILIPPS L, Porta N, James N, Huddart R, et al
    Differences in Quality of Life and Toxicity for Male and Female Patients following Chemo(radiotherapy) for Bladder Cancer.
    Clin Oncol (R Coll Radiol). 2023 Feb 11:S0936-6555(23)00052.
    PubMed         Abstract available
    
    

    
    Comput Methods Programs Biomed

20. LI J, Qiu Z, Cao K, Deng L, et al
    Predicting muscle invasion in bladder cancer based on MRI: A comparison of radiomics, and single-task and multi-task deep learning.
    Comput Methods Programs Biomed. 2023;233:107466.
    PubMed         Abstract available
    
    

    
    Diagnostics (Basel)

21. HU X, Xue Y, Zhu G
    Clinical Characteristics and Current Status of Treatment for Recurrent Bladder Cancer after Surgeries on Upper Tract Urothelial Carcinoma.
    Diagnostics (Basel). 2023;13:1004.
    PubMed         Abstract available
    
    

    
    EBioMedicine

22. WANG P, Shi Y, Zhang J, Shou J, et al
    UCseek: ultrasensitive early detection and recurrence monitoring of urothelial carcinoma by shallow-depth genome-wide bisulfite sequencing of urinary sediment DNA.
    EBioMedicine. 2023;89:104437.
    PubMed         Abstract available
    
    

    
    Eur Urol

23. GRIVAS P, Kopyltsov E, Su PJ, Parnis FX, et al
    Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma.
    Eur Urol. 2023;83:320-328.
    PubMed         Abstract available
    
    
24. BERGEROT CD, Gupta S
    Time to Rethink Quality of Life Assessment in Patients with Urothelial Cancer in the Current Therapeutic Era?
    Eur Urol. 2023;83:329-330.
    PubMed        
    
    
25. MOLINA GE, Schwartz B, Srinivas S, Shah S, et al
    In Patients with Advanced Urothelial Carcinoma, Immune Checkpoint Inhibition Prior to Enfortumab Vedotin Is Associated with High-grade Skin Toxicity.
    Eur Urol. 2023;83:377-378.
    PubMed        
    
    
26. MAITRE P, Sangar V, Choudhury A
    ADAPT and Improvise: Overcoming Bacillus Calmette-Guerin Unresponsiveness in Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2023 Mar 8:S0302-2838(23)02627-1. doi: 10.1016/j.eururo.2023.
    PubMed        
    
    
27. GIL-JIMENEZ A, van Dorp J, Contreras-Sanz A, van der Vos K, et al
    Corrigendum to "Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer" [Eur Urol 2023;83:313-17].
    Eur Urol. 2023 Mar 10:S0302-2838(23)02641-6. doi: 10.1016/j.eururo.2023.
    PubMed        
    
    

    
    Eur Urol Oncol

28. GROBET-JEANDIN E, Lenfant L, Mir C, Giannarini G, et al
    A Systematic Review of Oncological Outcomes Associated with Bladder-sparing Strategies in Patients Achieving Complete Clinical Response to Initial Systemic Treatment for Localized Muscle-invasive Bladder Cancer.
    Eur Urol Oncol. 2023 Mar 9:S2588-9311(23)00040-8. doi: 10.1016/j.euo.2023.
    PubMed         Abstract available
    
    

    
    Front Immunol

29. XU Y, Xia Z, Sun X, Wei B, et al
    Identification of a glutamine metabolism reprogramming signature for predicting prognosis, immunotherapy efficacy, and drug candidates in bladder cancer.
    Front Immunol. 2023;14:1111319.
    PubMed         Abstract available
    
    

    
    Front Oncol

30. ILLIAS AM, Yu KJ, Wu SC, Cata JP, et al
    Association of regional anesthesia with oncological outcomes in patients receiving surgery for bladder cancer: A meta-analysis of observational studies.
    Front Oncol. 2023;13:1097637.
    PubMed         Abstract available
    
    

    
    Front Public Health

31. TIAN YQ, Yang JC, Hu JJ, Ding R, et al
    Trends and risk factors of global incidence, mortality, and disability of genitourinary cancers from 1990 to 2019: Systematic analysis for the Global Burden of Disease Study 2019.
    Front Public Health. 2023;11:1119374.
    PubMed         Abstract available
    
    

    
    Front Surg

32. HU B, Chen R, Chen G, Zheng P, et al
    Prognostic nomogram for estimating survival in patients with resected muscle-invasive bladder cancer receiving chemotherapy.
    Front Surg. 2023;10:1121184.
    PubMed         Abstract available
    
    

    
    Gene

33. VAROL N, Keles I, Yildiz H, Karaosmanoglu C, et al
    Methylation analysis of histone 4-related gene HIST1H4F and its effect on gene expression in bladder cancer.
    Gene. 2023;866:147352.
    PubMed         Abstract available
    
    

    
    Hum Exp Toxicol

34. ZHU H, Chen Q, Zhang Y, Zhao L, et al
    Glutathione S-transferase zeta 1 alters the HMGB1/GPX4 axis to drive ferroptosis in bladder cancer cells.
    Hum Exp Toxicol. 2023;42:9603271231161606.
    PubMed         Abstract available
    
    

    
    Int J Mol Sci

35. ZUCCHI A, Claps F, Pastore AL, Perotti A, et al
    Focus on the Use of Resveratrol in Bladder Cancer.
    Int J Mol Sci. 2023;24:4562.
    PubMed         Abstract available
    
    
36. TORTORA F, La Civita E, Trivedi P, Febbraio F, et al
    Emerging RNA-Based Therapeutic and Diagnostic Options: Recent Advances and Future Challenges in Genitourinary Cancers.
    Int J Mol Sci. 2023;24:4601.
    PubMed         Abstract available
    
    
37. MA L, Chen H, Yang W, Ji Z, et al
    Crosstalk between Mesenchymal Stem Cells and Cancer Stem Cells Reveals a Novel Stemness-Related Signature to Predict Prognosis and Immunotherapy Responses for Bladder Cancer Patients.
    Int J Mol Sci. 2023;24:4760.
    PubMed         Abstract available
    
    
38. MURAKAMI K, Furuya H, Hokutan K, Goodison S, et al
    Association of SNPs in the PAI1 Gene with Disease Recurrence and Clinical Outcome in Bladder Cancer.
    Int J Mol Sci. 2023;24:4943.
    PubMed         Abstract available
    
    

    
    Int J Urol

39. MATSUMOTO K
    Editorial Comment on Validation of the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non-muscle invasive bladder cancer: A multi-institutional collaborative study.
    Int J Urol. 2023 Mar 16. doi: 10.1111/iju.15177.
    PubMed        
    
    

    
    J Clin Med

40. FLAMMIA RS, Tufano A, Chierigo F, Wurnschimmel C, et al
    The Effect of Sex on Disease Stage and Survival after Radical Cystectomy in Non-Urothelial Variant-Histology Bladder Cancer.
    J Clin Med. 2023;12:1776.
    PubMed         Abstract available
    
    
41. WANG Z, Wang T, Wu G, Zhu L, et al
    Clinical Significance and Tumor Microenvironment Characterization of a Novel Immune-Related Gene Signature in Bladder Cancer.
    J Clin Med. 2023;12:1892.
    PubMed         Abstract available
    
    

    
    J Laparoendosc Adv Surg Tech A

42. ZHAO Q, Wu L, Yang F, Han S, et al
    Application of Transvaginal Natural Orifice Specimen Extraction Surgery in Urological Surgery.
    J Laparoendosc Adv Surg Tech A. 2023;33:231-235.
    PubMed         Abstract available
    
    

    
    J Urol

43. PENG CK, Sung WW
    Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification. Letter.
    J Urol. 2023;209:676-677.
    PubMed        
    
    
44. LOTAN Y, Raman JD, Konety B, Daneshmand S, et al
    Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification.
    J Urol. 2023;209:762-772.
    PubMed         Abstract available
    
    

    
    Medicine (Baltimore)

45. HUANG Y, Xie C, Li Q, Huang X, et al
    Prognostic factors and nomogram for the overall survival of bladder cancer bone metastasis: A SEER-based study.
    Medicine (Baltimore). 2023;102:e33275.
    PubMed         Abstract available
    
    

    
    Molecules

46. PEREIRA IOA, da Silva GN, Almeida TC, Lima APB, et al
    LncRNA JHDM1D-AS1 Is a Key Biomarker for Progression and Modulation of Gemcitabine Sensitivity in Bladder Cancer Cells.
    Molecules. 2023;28:2412.
    PubMed         Abstract available
    
    

    
    Nat Rev Clin Oncol

47. VAN HOOGSTRATEN LMC, Vrieling A, van der Heijden AG, Kogevinas M, et al
    Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice.
    Nat Rev Clin Oncol. 2023 Mar 13. doi: 10.1038/s41571-023-00744.
    PubMed         Abstract available
    
    

    
    Naunyn Schmiedebergs Arch Pharmacol

48. WANG SS, Zhai GQ, Huang ZG, Luo JY, et al
    Nitidine chloride regulates cell function of bladder cancer in vitro through downregulating Lymphocyte antigen 75.
    Naunyn Schmiedebergs Arch Pharmacol. 2023.
    PubMed         Abstract available
    
    

    
    Neurourol Urodyn

49. CALEN L, Mesnard B, Hedhli O, Broudeur L, et al
    Robot-assisted laparoscopic cystectomy with non-continent urinary diversion for neurogenic lower urinary tract dysfunction: Midterm outcomes.
    Neurourol Urodyn. 2023;42:586-596.
    PubMed         Abstract available
    
    

    
    Panminerva Med

50. WU W, Jing Y, Xu Q, Hao J, et al
    MiR-9 promotes proliferation and inhibits apoptosis of bladder cancer cells via notch signaling pathway.
    Panminerva Med. 2023;65:114-115.
    PubMed        
    
    

    
    Pathol Res Pract

51. KUMAR R, Harilal S, Abdelgawad MA, Ghoneim MM, et al
    Urachal carcinoma: The journey so far and the road ahead.
    Pathol Res Pract. 2023;243:154379.
    PubMed         Abstract available
    
    

    
    Prog Urol

52. CIMIER A, Thach S, Lacroix B, Mariat C, et al
    [Evaluation of the efficacy and safety of HIVEC intravesical thermochemotherapy with intermediate-risk and high-risk non-muscle-invasive bladder cancer].
    Prog Urol. 2023 Mar 9:S1166-7087(23)00062-3. doi: 10.1016/j.purol.2023.
    PubMed         Abstract available
    
    

    
    Sci Rep

53. LI Z, Zhao J, Huang X, Wang J, et al
    An m7G-related lncRNA signature predicts prognosis and reveals the immune microenvironment in bladder cancer.
    Sci Rep. 2023;13:4302.
    PubMed         Abstract available
    
    

    
    Stem Cell Investig

54. BORDELEAU F, Brownell D, Chabaud S, Huot ME, et al
    Recreating heterogeneity of bladder cancer microenvironment to study its recurrences and progression.
    Stem Cell Investig. 2023;10:5.
    PubMed        
    
    

    
    Tissue Cell

55. ZHANG P, Sun Y, Shi L, Sun D, et al
    Effect of isorhamnetin on carbonic anhydrase IX expression and tumorigenesis of bladder cancer by activating PPARgamma/PTEN/AKT pathway.
    Tissue Cell. 2023;82:102048.
    PubMed         Abstract available
    
    

    
    Transl Androl Urol

56. YUAN F, Yin XY, Huang Y, Cai XW, et al
    Exosomal miR-93-5p as an important driver of bladder cancer progression.
    Transl Androl Urol. 2023;12:286-299.
    PubMed         Abstract available
    
    
57. YING Y, Wang Z, Tan Y, Cao H, et al
    Identification and validation of immunohistochemical marker panels to predict the prognosis of muscle invasive bladder cancer.
    Transl Androl Urol. 2023;12:176-186.
    PubMed         Abstract available
    
    
58. TAN Z, Chen Z, Yao G, Mumin MA, et al
    Neoadjuvant and adjuvant chemotherapy share equivalent efficacy in improving overall survival and cancer-specific survival among muscle invasive bladder cancer patients who undergo radical cystectomy: a retrospective cohort study based on SEER databas
    Transl Androl Urol. 2023;12:330-346.
    PubMed         Abstract available
    
    
59. ZHU J, Livasy C, Donahue EE, Symanowski JT, et al
    Prognostic value of galectin-1 and galectin-3 expression in localized urothelial bladder cancer.
    Transl Androl Urol. 2023;12:228-240.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: